CSM Advisors LLC Makes New $19.37 Million Investment in Johnson & Johnson $JNJ

CSM Advisors LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 126,825 shares of the company’s stock, valued at approximately $19,372,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sound View Wealth Advisors Group LLC raised its stake in Johnson & Johnson by 0.9% during the second quarter. Sound View Wealth Advisors Group LLC now owns 70,743 shares of the company’s stock worth $10,806,000 after purchasing an additional 624 shares during the period. Campbell & CO Investment Adviser LLC increased its holdings in shares of Johnson & Johnson by 1,165.7% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 27,466 shares of the company’s stock worth $4,195,000 after buying an additional 25,296 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Johnson & Johnson by 45.9% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 173,936 shares of the company’s stock valued at $26,569,000 after buying an additional 54,683 shares during the period. Delta Financial Advisors LLC lifted its holdings in Johnson & Johnson by 0.5% in the second quarter. Delta Financial Advisors LLC now owns 25,853 shares of the company’s stock valued at $3,949,000 after acquiring an additional 141 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Johnson & Johnson by 6.9% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,822,070 shares of the company’s stock worth $736,658,000 after acquiring an additional 310,156 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Stifel Nicolaus upped their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research report on Wednesday, October 15th. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target for the company in a research report on Monday, October 20th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Finally, Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Stock Down 0.3%

Shares of JNJ opened at $186.50 on Friday. The company’s 50-day simple moving average is $184.25 and its 200-day simple moving average is $168.70. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48. The stock has a market capitalization of $449.34 billion, a PE ratio of 18.00, a P/E/G ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.